The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://lawsonubhp141152.tokka-blog.com/39227691/retatrutide-vs-tirzepatide-a-comparative-analysis